{
    "clinical_study": {
        "@rank": "139661", 
        "arm_group": [
            {
                "arm_group_label": "Adalimumab (ADA)", 
                "arm_group_type": "Active Comparator", 
                "description": "Adalimumab (ADA) sc eow (subcutaneous every other week) starting 1 week after initial loading dose"
            }, 
            {
                "arm_group_label": "Placebo (PBO) Arm", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (PBO) Arm:  Matching Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to assess the safety and efficacy of adalimumab in subjects\n      with nail psoriasis."
        }, 
        "brief_title": "A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Nail Psoriasis", 
            "Plaque Psoriasis"
        ], 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult subjects with clinical diagnosis of chronic plaque psoriasis (with a disease\n             duration of at least 6 months) and at least 1 fingernail with nail psoriasis.\n\n          -  Subject must have BSA \u2265 10% and a target fingernail mNAPSI \u2265 8 at Week 0, OR BSA \u2265\n             5%, a target fingernail mNAPSI \u2265 8 and a total mNAPSI score of \u2265 20 at Week 0.\n\n          -  Subject must have a Nail Psoriasis Physical Functioning Severity score of > 3, OR a\n             Nail Psoriasis Pain NRS score of >3.\n\n          -  Subjects must have a Physician's Global Assessment (PGA) of Fingernail Psoriasis and\n             a PGA of Skin Psoriasis of at least moderate.\n\n          -  Subject must have discontinued use of all systemic therapies for the treatment of\n             psoriasis, or systemic therapies known to improve psoriasis for at least 4 weeks\n             prior to Week 0, ustekinumab must have been discontinued at least 12 weeks prior to\n             Week 0.\n\n          -  Target fingernail must have mNAPSI score of \u2265 8.\n\n          -  Adult subjects with clinical diagnosis of chronic.\n\n        Exclusion Criteria:\n\n          -  Prior adalimumab therapy.\n\n          -  Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or\n             viral) that may interfere with evaluation of skin or fingernail psoriasis.\n\n          -  Recent infection requiring treatment.\n\n          -  Significant medical events or conditions that may put patients at risk for\n             participation, including recent history of drug or alcohol abuse.\n\n          -  Female subjects who are pregnant or breast-feeding or considering becoming pregnant\n             during the study.\n\n          -  History of cancer, except successfully treated skin cancer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016482", 
            "org_study_id": "M13-674", 
            "secondary_id": "2013-003275-36"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Adalimumab (ADA)", 
                    "Placebo (PBO) Arm"
                ], 
                "description": "Adalimumab (ADA)", 
                "intervention_name": "Adalimumab (ADA)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo (PBO) Arm", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Plaque Psoriasis", 
            "Nail Psoriasis"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "Site Reference ID/Investigator# 116745"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116745", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bakersfield", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93309"
                    }, 
                    "name": "Site Reference ID/Investigator# 116741"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116741", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burbank", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91505"
                    }, 
                    "name": "Site Reference ID/Investigator# 116884"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116884", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33624"
                    }, 
                    "name": "Site Reference ID/Investigator# 116750"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116750", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68144"
                    }, 
                    "name": "Site Reference ID/Investigator# 116772"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116772", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Henderson", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89074"
                    }, 
                    "name": "Site Reference ID/Investigator# 116797"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116797", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Windsor", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08520"
                    }, 
                    "name": "Site Reference ID/Investigator# 119597"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 119597", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Site Reference ID/Investigator# 116771"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116771", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Site Reference ID/Investigator# 116747"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116747", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Carlton", 
                        "country": "Australia", 
                        "zip": "3053"
                    }, 
                    "name": "Site Reference ID/Investigator# 118075"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118075", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kogarah", 
                        "country": "Australia", 
                        "zip": "2217"
                    }, 
                    "name": "Site Reference ID/Investigator# 118076"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118076", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phillip", 
                        "country": "Australia", 
                        "zip": "2606"
                    }, 
                    "name": "Site Reference ID/Investigator# 116495"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116495", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Site Reference ID/Investigator# 116515"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116515", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Site Reference ID/Investigator# 122415"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 122415", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1090"
                    }, 
                    "name": "Site Reference ID/Investigator# 118096"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118096", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ghent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "Site Reference ID/Investigator# 116516"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116516", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Markham", 
                        "country": "Canada", 
                        "zip": "L3P 1A8"
                    }, 
                    "name": "Site Reference ID/Investigator# 117977"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117977", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1V 4X7"
                    }, 
                    "name": "Site Reference ID/Investigator# 117980"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117980", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waterloo", 
                        "country": "Canada", 
                        "zip": "N2J 1C4"
                    }, 
                    "name": "Site Reference ID/Investigator# 117979"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117979", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France", 
                        "zip": "33604"
                    }, 
                    "name": "Site Reference ID/Investigator# 120395"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 120395", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poitiers", 
                        "country": "France", 
                        "zip": "86021"
                    }, 
                    "name": "Site Reference ID/Investigator# 116536"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116536", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Site Reference ID/Investigator# 116636"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116636", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }, 
                    "name": "Site Reference ID/Investigator# 117983"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117983", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "Site Reference ID/Investigator# 120777"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 120777", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "16121"
                    }, 
                    "name": "Site Reference ID/Investigator# 116640"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116640", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "16121"
                    }, 
                    "name": "Site Reference ID/Investigator# 116642"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116642", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "124 62"
                    }, 
                    "name": "Site Reference ID/Investigator# 117985"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117985", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monterrey", 
                        "country": "Mexico", 
                        "zip": "CP 64460"
                    }, 
                    "name": "Site Reference ID/Investigator# 118863"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118863", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zapopan", 
                        "country": "Mexico", 
                        "zip": "CP 45190"
                    }, 
                    "name": "Site Reference ID/Investigator# 118865"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118865", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Carolina", 
                        "country": "Puerto Rico", 
                        "zip": "00985"
                    }, 
                    "name": "Site Reference ID/Investigator# 116720"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116720", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Belgium", 
                "Canada", 
                "France", 
                "Germany", 
                "Greece", 
                "Mexico", 
                "Puerto Rico"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects With Chronic Plaque Psoriasis", 
        "other_outcome": [
            {
                "description": "Proportion of subjects with a 75% improvement in mNAPSI score", 
                "measure": "Proportion of subjects achieving a total-fingernail mNAPSI 75 response", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Physician's assessment of patient's fingernails that meet definition of clear or minimal.", 
                "measure": "Proportion of subjects achieving PGA-F of \"clear\" or \"minimal\"", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Physician's assessment of patient's fingernails that meet definition of clear or minimal among those with a nail bed component of \"moderate\" for worse.", 
                "measure": "Proportion of subjects achieving \"clear\" or \"minimal\" in nail bed component of the PGA-F, among those with a nail bed component of \"moderate\" or worse.", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Physician's assessment of patient's fingernails that meet definition of clear or minimal among those with a nail matrix component of \"moderate\" or worse.", 
                "measure": "Proportion of subjects achieving \"clear\" or \"minimal\" in nail matrix component of the PGA-F, among those with a nail matrix component of \"moderate\" or worse.", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Proportion of subjects achieving mNAPSI = 0 in target fingernail.", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Proportion of subjects achieving mNAPSI = 0 of all fingernails", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Proportion of subjects achieving mNAPSI \u2264 2 of the target fingernail", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Proportion of subjects achieving mNAPSI \u2264 2 of all fingernails", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in mNAPSI of the target fingernail", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in mNAPSI score of all fingernails", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Proportion of subjects achieving NAPSI=0 in all fingernails", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Proportion of subjects achieving NAPSI=0 in target fingernail", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in total NAPSI of of target fingernail", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in total NAPSI of all fingernails", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in Psoriasis Area Severity Index (PASI)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Proportion of subjects achieving total PASI 75/50/90/100 among subjects with PASI score \u2265 5", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Physician's assessment of patient's skin psoriasis that meets definition of clear or minimal", 
                "measure": "Proportion of subjects achieving physician's global assessment of skin psoriasis (PGA-S) \"clear\" or \"minimal\"", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in total body surface area (BSA)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in Nail Psoriasis Pain Numeric Rating Scale (NRS)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in Nail Psoriasis Physical Functioning Severity Score", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in dermatology life quality index (DLQI)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Proportion of subjects achieving DLQI of 0, and achieving DLQI of 0/1", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in EuroQol-5Dimensions-5Levels (EQ-5D-5L) Health Status Assessment", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in Hospital Anxiety Depression Scale (HADS)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Proportion of subjects with a new diagnosis of psoriatic arthritis (PsA) during the study (with adverse event of PsA) among subjects without PsA.", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Change in Nail Psoriasis Quality of Life (Nail PsQoL)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Percent change in mNAPSI of the target fingernail", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Percent change in mNAPSI score of all fingernails", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Percent change in total NAPSI of target fingernail", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Percent change in total NAPSI of all fingernails", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Percent change in Psoriasis Area Severity Index (PASI) of all fingernails", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Percent change in total body surface area (BSA)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Percent change in Nail Psoriasis Pain Numeric Rating Scale (NRS)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Percent change in Nail Psoriasis Physical Functioning Severity Score", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Percent change in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Physician's assessment of patient's fingernails that meet definition of clear", 
                "measure": "Proportion of subjects acheiving PGA-F of \"clear\"", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Physician's assessment of patient's skin psoriasis that meets definition of clear", 
                "measure": "Proportion of subjects acheiving PGA-S of \"clear\"", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Subjects with 50% improvement in the scalp component of the B-SNIPI among subjects with scalp score of 6 and greater at Week 0", 
                "measure": "Proportion of subjects achieving 50% improvement in the scalp component of Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Subjects achieving 50% improvement in inverse psoriasis component among subjects with inverse psoriasis score of 6 and greater at Week 0.", 
                "measure": "Proportion of subjects acheiving 50% improvement in inverse psoriasis component of the B-SNIPI", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }
        ], 
        "overall_contact": {
            "email": "sarah.maddux@abbvie.com", 
            "last_name": "Sarah K Maddux, BS", 
            "phone": "847-937-2178"
        }, 
        "overall_contact_backup": {
            "email": "lacheir.hopkins@abbvie.com", 
            "last_name": "La'Cheir S Hopkins, BS", 
            "phone": "847-935-6434"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Dawn  M Carlson, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Belgium: Ethics Committee", 
                "Germany: Paul-Ehrlich-Institut", 
                "Australia: Human Research Ethics Committee", 
                "France: Committee for the Protection of Personnes", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Greece: National Organization of Medicines"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Subjects achieving a 75% reduction in total mNAPSI of all fingernails", 
                "measure": "Proportion of subjects achieving a total-fingernail modified Nail Psoriasis Severity Index (mNAPSI) 75 response", 
                "safety_issue": "No", 
                "time_frame": "At Week 26"
            }, 
            {
                "description": "Physician's assessment of patient's fingernails that meet definition of clear or minimal.", 
                "measure": "For US regulatory purposes: Proportion of subjects with a Physician's Global Assessment of Fingernails of \"clear\" or \"minimal\"", 
                "safety_issue": "No", 
                "time_frame": "At Week 26"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016482"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "For Ex-US sites: Percent change in total mNAPSI of all fingernails", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Subjects who achieve a mNAPSI score of 0", 
                "measure": "For Ex-US: Proportion of subjects achieving mNAPSI = 0 in all fingernails", 
                "safety_issue": "No", 
                "time_frame": "At Week 26"
            }, 
            {
                "measure": "For Ex-US: Change in Nail Psoriasis Pain Numeric Rating Scale (NRS)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "For Ex-US: Change in Nail Psoriasis Physical Functioning Severity Score", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Subjects with 50% improvement in the scalp component among subjects with scalp score of 6 or greater at Week 0", 
                "measure": "For Ex-US: Proportion of subjects with at least 50% improvement in the scalp component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI)", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 26"
            }, 
            {
                "measure": "For Ex-US: Proportion of subjects achieving Physician's Global Assessment of Fingernails (PGA-F) of \"Clear\" or \"minimal\"", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 26"
            }, 
            {
                "description": "Subjects with at least a 75% reduction in total mNAPSI of all fingernails.", 
                "measure": "For US: Proportion of subjects acheiving a total mNAPSI 75 response", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 26"
            }, 
            {
                "measure": "For US: Percent change in total mNAPSI of all fingernails", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 26"
            }, 
            {
                "description": "Proportion of subjects mNAPSI = 0", 
                "measure": "For US: Proportion of subjects achieving mNAPSI = 0 in all fingernails", 
                "safety_issue": "No", 
                "time_frame": "At Week 26"
            }, 
            {
                "measure": "For US: Change in Nail Psoriasis Pain Numeric Rating Scale (NRS)", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 26"
            }, 
            {
                "measure": "For US: Change in Nail Psoriasis Physical Functioning Severity Score", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 26"
            }, 
            {
                "description": "Subjects with 50% improvement in the scalp component among subjects with scalp score of 6 or greater at Week 0", 
                "measure": "For US: Proportion of subjects with at least 50% improvement in the scalp component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI)", 
                "safety_issue": "No", 
                "time_frame": "Week 0 to Week 26"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}